CPT 80370 Skeletal Muscle Relaxant Panel Reimbursement

CPT code 80370 denotes laboratory testing to detect or quantify three or more skeletal muscle relaxants in a patient specimen. This multi-analyte toxicology panel is clinically important for monitoring therapeutic regimens, assessing suspected overdose or poisoning, and evaluating drug exposure in perioperative or acute care settings. At a national level, accurate coding of 80370 supports appropriate laboratory reimbursement, clinical documentation, and utilization tracking for drug monitoring programs.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks for payer coverage patterns, common billing modifiers observed in practice, and clinical context explaining when multi-drug skeletal muscle relaxant testing is applied. The publication outlines coding nuances for laboratory service lines and typical sites of service, and it summarizes policy considerations that influence test utilization and claims adjudication.

This overview is intended to inform coding staff, laboratory managers, and health policy analysts about the clinical purpose of 80370, payer coverage landscape, and the operational contexts in which this code is used. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 80370 describes laboratory testing that measures the amount of, or detects the presence of, three or more skeletal muscle relaxants in a patient specimen. These drugs act to reduce skeletal muscle tone and are used to alleviate muscle spasm and pain. The procedure reflects multi-analyte toxicology screening specific to skeletal muscle relaxant agents.

Service Type: Laboratory / Toxicology Testing

Typical Site of Service: Clinical laboratory or hospital laboratory

Clinical Context

A middle-aged outpatient presents to a hospital laboratory or an outpatient collection center after recent surgery and a short inpatient stay. The clinician ordered a comprehensive toxicology screen focused on skeletal muscle relaxants because the patient experienced unexplained excessive sedation, respiratory depression, or a suspected medication interaction with opioid analgesics. A blood or urine specimen is collected following standard chain-of-custody or routine lab procedures. The specimen is sent to the clinical chemistry/toxicology lab where an analytical method (e.g., immunoassay screening followed by confirmatory chromatography/mass spectrometry) is used to detect and quantify three or more skeletal muscle relaxants in the specimen. Results are reported to the ordering provider and documented in the electronic health record; interpretation may influence medication reconciliation, discharge planning, or urgent reversal and monitoring decisions.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Standard use when no specific modifier applies
`26`	Professional component	Use when billing only the professional (interpretive) portion of the laboratory test

Taxonomy Code	Specialty	Notes
362LP0800X	Clinical Laboratory	Laboratory personnel and medical directors performing toxicology testing
2080P0207X	Pathology	Pathologists who supervise and interpret complex confirmatory toxicology results
207L00000X	Anatomic and Clinical Pathology	Clinical pathologists responsible for test validation and reporting
163W00000X	Emergency Medicine	Emergency physicians who commonly order urgent toxicology panels
207K00000X	Neurology	Neurologists who may evaluate patients for drug-induced neuromuscular effects

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R40.0`	Somnolence	Reflects excess sedation where muscle relaxant levels may contribute
`R06.4`	Hyperventilation	May co-occur with respiratory effects prompting drug-level assessment
`R06.02`	Shortness of breath	Respiratory compromise can be caused or worsened by sedative muscle relaxants
`T42.3X1A`	Poisoning by benzodiazepines, accidental (initial encounter)	Relevant when benzodiazepine-type muscle relaxants are suspected contributors
`T43.6X1A`	Poisoning by other anticonvulsants and sedative-hypnotics, accidental (initial encounter)	Some agents overlap with skeletal muscle relaxant toxicity profiles
`M62.81`	Muscle weakness	Symptom that may prompt evaluation for drug-induced neuromuscular depression
`G72.81`	Critical illness myopathy	Differentiation from drug-induced muscle weakness may require toxicology testing
`Z91.110`	Patient's noncompliance with medication regimen	Relevant in contexts assessing whether multiple muscle relaxants were taken concurrently

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80370`	Therapeutic drug assay; analysis for three or more skeletal muscle relaxants	Primary code describing detection/measurement of three or more skeletal muscle relaxants in a specimen
`80305`	Drug test(s), presumptive, any number of drug classes; any number of techniques, each drug class	Often used as initial immunoassay screening prior to confirmatory testing for specific muscle relaxants
`80307`	Drug test(s), any number of drug classes, confirmatory, each procedure	Used for confirmatory testing (e.g., GC-MS or LC-MS/MS) after presumptive positive screens for specific skeletal muscle relaxants
`80101`	Drug confirmation, quantitative, 1-2 drug classes	May be used when quantitative confirmation for a smaller panel or specific drugs is required alongside broader panels
`99213`	Office or other outpatient visit, established patient	Represents typical clinician evaluation visit where ordering, review, and follow-up of toxicology results occur

OpenPayer

Summary & Overview

CPT 80370: Detection of Three or More Skeletal Muscle Relaxants